Merck MRK

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Ex-Bank of New York Mellon employee pleads guilty to insider trading

      Headlines

      Fri, 24 Oct 2014

      NEW YORK (Reuters) - A former Bank of New York Mellon Corp employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc employee about potential pharmaceutical mergers.

    2. UPDATE 1-Ex-Bank of New York Mellon employee pleads guilty to insider trading

      Headlines

      Fri, 24 Oct 2014

      NEW YORK, Oct 24 (Reuters) - A former Bank of New York Mellon Corp employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc employee about potential pharmaceutical mergers.

    3. Ex-Bank of New York Mellon trader pleads guilty to insider trading

      Headlines

      Fri, 24 Oct 2014

      NEW YORK, Oct 24 (Reuters) - A former Bank of New York Mellon Corp trader on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc employee about potential...

    4. Is Merck The Right Dividend Stock To Have In A Portfolio?

      Headlines

      Fri, 24 Oct 2014

      Is Merck The Right Dividend Stock To Have In A Portfolio?

    5. Bristol Posts Solid 3Q With Robust Eliquis Sales as Focus Remains on Strong Expected Opdivo Launch

      Commentary

      Fri, 24 Oct 2014

      of lung cancer, we expect melanoma ($3 billion market) to represent the next important opportunity for Opdivo, but Merck ’s competing drug Keytruda was recently approved in the U.S., which may limit the potential for Opdivo in melanoma

    6. Sigma-Aldrich Meets Expectations Prior to Merck Deal

      Commentary

      Thu, 23 Oct 2014

      unchanged, and our $140 fair value estimate already reflects Merck KGaA’s acquisition price. Although management noted strong ..... performance in the coming quarters. We still expect the Merck KGaA deal to close in early 2015.

    7. Gilead Sciences: Clear The Dockets And Settle With Merck Already

      Headlines

      Tue, 21 Oct 2014

      Gilead Sciences: Clear The Dockets And Settle With Merck Already

    8. Members of Big Pharma to square off at breast cancer meeting

      Headlines

      Fri, 17 Oct 2014

      Roche ( OTCQX:RHHBY ) and Merck (NYSE: MRK ) are set to present data from their respective immunotherapy ..... melanoma and lung, bladder, kidney, bowel and blood cancers. Merck 's product, Keytruda (pembrolizumab) injection, is currently

    9. UPDATE 1-Roche, Merck extend immunotherapy fight to breast cancer

      Headlines

      Fri, 17 Oct 2014

      (Adds Merck also presenting breast cancer data in December)

    10. Merck and Ranbaxy settle Medicaid suits

      Headlines

      Thu, 16 Oct 2014

      Without admitting to any wrongdoing, Merck 's ( MRK -2% ) Organon unit agrees to pay $31M to settle allegations ..... antidepressant and promoted it for non-approved indications. Merck acquired Organon as part of its takeover of Schering-Plough

    « Prev12345Next »
    Content Partners